Precision mRNA Nanomedicine for Targeted Vascular Therapies in ARDS and Atherosclerosis

Zhou, Z.; Zhu, J.; Yeh, C.-F.; Meliton, A.; Wu, D.; Huang, R.-T.; Shentu, T.-P.; Ray, A. G.; Wiseman, D.; Budina, E.; Alpar, A. T.; Yang, K.-C.; Hubbell, J.; Weinstock, A.; Mutlu, G. M.; Tirrell, M. V.; Fang, Y.

doi:10.1101/2025.01.09.632179

bioRxiv · 10.1101/2025.01.09.632179

Precision mRNA Nanomedicine for Targeted Vascular Therapies in ARDS and Atherosclerosis

Zhou, Z.·Zhu, J.·Yeh, C.-F.·Meliton, A.·Wu, D.·Huang, R.-T.·Shentu, T.-P.·Ray, A. G.·Wiseman, D.·Budina, E.·Alpar, A. T.·Yang, K.-C.·Hubbell, J.·Weinstock, A.·Mutlu, G. M.·Tirrell, M. V.·Fang, Y.

View original source ↗Export metadata ↓

Abstract

Vascular diseases, including acute respiratory distress syndrome (ARDS) and atherosclerosis, are leading causes of global morbidity and mortality, underscoring the critical need for innovative therapies. While human genetics has uncovered specific molecular mechanisms in endothelial cells that drive acute and chronic vascular inflammation central to these conditions, effective in vivo strategies to spatiotemporally target these disease-causing pathways using therapeutic mRNAs remain limited. Here, we present a modular and tunable nanoparticle platform (PROGRAMMED nanoparticles) engineered to selectively deliver therapeutic mRNAs to target cells with distinct molecular signatures, such as inflamed endothelial cells expressing vascular cell adhesion molecule 1 (VCAM1). This approach restores key genetics-informed endothelial pathways implicated in disease, including the loss of Kruppel-like factor 2 (KLF2) in acute inflammation underlying ARDS and the suppression of phospholipid phosphatase 3 (PLPP3) in chronic inflammation driving atherosclerosis. In multiple preclinical models, these precision mRNA nanomedicine strategies demonstrated compelling therapeutic efficacy. VCAM1-targeting PROGRAMMED nanoparticles delivering KLF2 mRNA to inflamed lung microvascular endothelial cells significantly improved microvascular health and alleviated virus-induced ARDS. Similarly, PLPP3 mRNA delivery by VCAM1-targeting PROGRAMMED nanoparticles attenuated arterial inflammation, slowed atherosclerosis progression, and promoted regression of advanced plaques. This innovative platform offers a transformative approach for spatiotemporal mRNA therapies targeting inflamed endothelial cells, providing a minimally invasive and highly specific strategy to address acute and chronic vascular diseases. Moreover, the modularity of PROGRAMMED nanoparticles, particularly their ability to display diverse targeting motifs, holds substantial potential for addressing a broad spectrum of vascular complications and other diseases that require precise spatiotemporal correction of dysregulated genes.

Explore related subjects

bioengineering Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Zhou, Z., Zhu, J., Yeh, C.-F., Meliton, A., Wu, D., Huang, R.-T., Shentu, T.-P., Ray, A. G., Wiseman, D., Budina, E., Alpar, A. T., Yang, K.-C., Hubbell, J., Weinstock, A., Mutlu, G. M., Tirrell, M. V., Fang, Y.. 2025-01-14. Precision mRNA Nanomedicine for Targeted Vascular Therapies in ARDS and Atherosclerosis. https://doi.org/10.1101/2025.01.09.632179

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

AtomWeaver: Multi-Component Flow Matching with a Structured Geometric Prior Facilitates Non-Canonical Peptide Design

Fixed-backbone sequence discovery, or inverse folding, is a critical recurring task in the development of new polypeptide therapeutics. Once promising backbones are established for a target pocket, computational inverse folding methods greatly help accelerate generation of candidate sequences. Such methods are mature for the traditional case of limiting to the fixed twenty-letter canonical vocabulary; however, they cannot access the broader space of non-canonical amino acids (NCAAs). This design constraint is exacerbated for peptide binders, a fast-growing modality that readily incorporates NCAAs, though in practice non-canonical design frequently depends on laborious medicinal-chemistry campaigns. An extension of inverse folding to NCAAs is thus critical to accelerating design of novel therapeutic peptides. AtomWeaver uses a joint all-site, atom-level generative scheme that does not restrict side-chain categorical assignment by either predetermined or co-resolving residue identity. Conditioned only on a fixed peptide backbone and its target protein, its multi-component flow guides side-chain atoms as unlabeled points in R3 from a nested shell prior to a variable-count final atom cloud. Identity is then read by matching each predicted cloud against a reference library of canonical and non-canonical templates. Since identity is decided only at decode time, the addressable vocabulary is a property of the library rather than of the trained weights: a new NCAA costs one reference structure and no retraining, and the model can select residues it was never prompted for and never saw in training. On a deep mutational scan of two peptide-target systems, AtomWeaver's canonical readout shows high observed mean agreement with experimental values among the compared inverse-folding methods. In the mixed canonical-noncanonical setting that canonical-only baselines cannot support at all, it likewise retains ranking signal across both systems. AtomWeaver also displayed self-consistent designs on de novo binder backbones, with the highest interface confidence among compared methods. Notably, it reached these metrics while achieving broad empirical coverage of our 300-residue vocabulary, including four non-canonical types never visible in training. AtomWeaver thus serves canonical and non-canonical peptide design alike, while transforming residue vocabulary to an expandable inference-time choice.

bioengineering↗

bioRxiv2026

The Influence of Obesity and Body Shape on Sagittal Plane Knee Kinematics and Kinetics during Obstacle Crossing

Altered walking mechanics in individuals with obesity can contribute to knee osteoarthritis. The gait deviations may become more pronounced during obstacle crossing. In women, body fat distribution may further influence knee load, especially when excess fat accumulates in the thighs and hips. However, relatively little is known about how regional fat distribution affects gait in women with obesity. This study investigated how obesity and, among women, different fat distributions (Apple: more abdominal fat; Pear: more lower-limb fat) influence knee biomechanics during walking with and without obstacle crossing. Participants were 15 controls without obesity (NB) and 27 with obesity (OB). Within female participants, 10 without obesity (fNB) were compared with 20 with obesity, stratified by waist-hip ratio (Apple:10, Pear:10). Speed-adjusted statistical parametric mapping applied a general linear model (NB vs. OB) and an analysis of covariance (fNB vs. Apple vs. Pear). OB exhibited a significantly greater late-stance knee extension moment than NB across all tasks, and this difference persisted among fNB, Apple, and Pear in obstacle tasks (p<0.05). OB walked with reduced knee flexion during the early-stance leading limb after crossing a medium-height obstacle (p=0.048) and a high-height obstacle (p=0.008) compared to NB. There were significant body-shape effects (p<0.05), and post-hoc comparisons confirmed that Pear had lower knee angles than fNB in both leading-limb conditions after crossing medium- and high-height obstacles (p=0.008 and p=0.001, respectively). These findings suggest that obstacle crossing helps illuminate how excess weight influences knee biomechanics, and how regional fat distribution modulates the degree of this alteration.

bioengineering↗

bioRxiv2026

RNASeek: A Cross-Phyla Generative Foundation Model for Multipurpose RNA Modeling and Reinforcement Learning-Based Design

RNA plays central roles in regulating information flow and provides a versatile substrate for engineering biological functions. While large language models (LLMs) have transformed natural language processing and protein design, a general framework connecting RNA foundation models to functional sequence design remains limited. Here, we present RNASeek, a 1.6-billion-parameter generative foundation model built on a DeepSeek architecture and trained on a cross-phyla transcriptomic corpus for RNA sequence representation and generation. Natural-language tokens enable flexible conditional prediction and sequence design using a unified backbone. RNASeek captures species-specific transcript features and intron-exon boundaries in a zero-shot setting. We then fine-tune RNASeek to predict ribozyme self-cleavage activity and viral mRNA stability, revealing interpretable sequence features associated with function, including ribozyme loop flexibility and stem stability, as well as AU-rich motifs associated with mRNA stability. We use these functional predictors as reward models and apply Group Relative Policy Optimization (GRPO) to update the generation policy of RNASeek toward sequences with desired properties. GRPO-guided generation produces faster-cleaving ribozymes and stability-enhancing 3' UTRs while satisfying user-specified IUPAC constraints. Experimentally validated RNASeek-generated ribozymes achieve wild-type levels of activity, while RNASeek-generated 3' UTR sequences exceed the performance of the training data and benchmarked AI-generated 3' UTRs. Together, RNASeek establishes a unified pretrain-predict-optimize framework that connects learned RNA function to controllable de novo sequence design and provides a general strategy for engineering regulatory RNAs with desired properties.

bioengineering↗